CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 226 enrolled
Drug / intervention
Roflumilast Foam 0.3% +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04091646
NCT04091646Phase 2Completed
CompareCT.gov

A Phase 2b, 8-Week, Parallel Group, Double Blind, Vehicle-Controlled Study of the Safety and Efficacy of ARQ-154 Foam 0.3% Administered QD in Subjects With Seborrheic Dermatitis

Arcutis Biotherapeutics, Inc.·interventional·Posted Sep 17, 2019·Updated Jul 3, 2023

In Brief

A Phase 2 clinical trial evaluating Roflumilast Foam 0.3% and Vehicle foam for Seborrheic Dermatitis. Completed, enrolled 226 participants across 24 sites in 2 countries.

Detailed Summary

This was a parallel group, double blind, vehicle-controlled study assessed the safety and efficacy of roflumilast foam (ARQ-154) vs placebo foam in participants with seborrheic dermatitis.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeborrheic Dermatitis
CountriesCanada, United States
Collaborators--

Timeline

Phase 2CompletedFinished
2020202120222023202420252026
First PostedSep 17, 2019
Enrollment StartDec 4, 2019
Primary CompletionAug 18, 2020
Study CompletionAug 21, 2020
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.8 years ago

Interventions

Roflumilast Foam 0.3%drug

Roflumilast foam for topical application.

Vehicle foamdrug

Vehicle foam for topical application.